Capitalizing on extrasynaptic glutamate neurotransmission to treat antipsychotic-resistant symptoms in schizophrenia.
Krystal
John H
JH
Department of Psychiatry, Yale University School of Medicine, and Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, Connecticut, USA. john.krystal@yale.edu
D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004351:Drug Resistance / Q000187:drug effects; D018698:Glutamic Acid / Q000378:metabolism*; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D009435:Synaptic Transmission / Q000187:drug effects*
D014150:Antipsychotic Agents; D018698:Glutamic Acid